AR048232A1 - Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 - Google Patents
Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4Info
- Publication number
- AR048232A1 AR048232A1 ARP050100409A ARP050100409A AR048232A1 AR 048232 A1 AR048232 A1 AR 048232A1 AR P050100409 A ARP050100409 A AR P050100409A AR P050100409 A ARP050100409 A AR P050100409A AR 048232 A1 AR048232 A1 AR 048232A1
- Authority
- AR
- Argentina
- Prior art keywords
- groups
- alkyl
- cycloalkyl
- halogen
- och2cf3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Se refiere a su uso en medicina, a composiciones que los contienen, a procesos para su preparacion y a intermedios usados en tales procesos. Reivindicacion 1: Un compuesto de formula general (1), o una sal farmacéuticamente aceptable, hidrato, solvato, isomero o profármaco del mismo, en la que R1 se selecciona entre: grupos -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-8, -cicloalquenilo C5-8, -alquilC1-2-cicloalquiloC3-8, arilo, -alquilarilo C1-2, heterociclilo o grupos alquilC1-2-heterocíclicos; donde cada uno de los grupos R1 anteriores está opcionalmente sustituido con uno o más grupos seleccionados entre: alquilo C1-4, -(CH2)mcicloalquiloC3-5, halogeno, -(CH2)mOR6, -CN, -C(O)OR6, -(CH2)mNR7SO2R8, CF3, CH2CF3, OCF3 o OCH2CF3, donde m = 0, 1 o 2; R2 es H, OH o OCH3; R3 se selecciona entre: grupos H, -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-8, -cicloalquenilo C5-8, -alquilC1-2-cicloalquiloC3-8, arilo, -alquilarilo C1-2, heterociclilo o grupos -alquilC1-2-heterocíclicos; donde cada uno de los ultimos diez grupos R3 está opcionalmente sustituido con uno o más grupos seleccionados entre: -OH, -alquilo C1-4, -(CH2)ncicloalquiloC3-5, halogeno, -CN, -(CH2)nOR6 o - (CH2)nNR7R8, donde n = 0, 1 o 2; R4 se selecciona entre: -H, -alquilo C1-4, -alquenilo C2-4, -alquinilo C2-4, -(CH2)pcicloalquiloC3-5, -(CH2)pciclo-alqueniloC5, halogeno, -(CH2)pOR6, (CH2)pNR7R8, -CN, -C(O)R6, -C(O)OR6, -C(O)NR7R8, -(CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 o OCH2CF3, donde p = 0, 1 o 2; R5 se selecciona entre: grupos -alquilo C1-4, -alquenilo C2-4, -alquinilo C2-4, -(CH2)pcicloalquiloC3-5, -(CH2)pciclo-alqueniloC5, halogeno, -(CH2)pOR6, (CH2)pNR7R8, -CN, -C(O)R6, -C(O)OR6, - C(O)NR7R8, -(CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 o OCH2CF3, donde p = 0, 1 o 2; o R4 y R5 pueden formar conjuntamente u anillo saturado o insaturado de 5 a 7 miembros condensado; cada uno de R6, R7 y R8 se selecciona independientemente entre H, CH3 o CH2CH3; y donde los grupos heterocíclicos de R1 y R3 se seleccionan independientemente entre sistemas de anillo de 4 a 10 miembros que contienen hasta 4 heteroátomos seleccionados independientemente entre O, N o S.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402492.3A GB0402492D0 (en) | 2004-02-04 | 2004-02-04 | Pharmaceutically active compounds |
| GB0412417A GB0412417D0 (en) | 2004-06-03 | 2004-06-03 | Pharmaceutically active compounds |
| GB0425530A GB0425530D0 (en) | 2004-11-19 | 2004-11-19 | Pharmaceutically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048232A1 true AR048232A1 (es) | 2006-04-12 |
Family
ID=34864830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100409A AR048232A1 (es) | 2004-02-04 | 2005-02-03 | Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1716135B1 (es) |
| JP (1) | JP4031814B2 (es) |
| KR (1) | KR100830763B1 (es) |
| CN (1) | CN1930146A (es) |
| AP (1) | AP2006003699A0 (es) |
| AR (1) | AR048232A1 (es) |
| AT (1) | ATE511507T1 (es) |
| AU (1) | AU2005213538A1 (es) |
| BR (1) | BRPI0507435A (es) |
| CA (1) | CA2555800C (es) |
| CR (1) | CR8545A (es) |
| EA (1) | EA011159B1 (es) |
| EC (1) | ECSP066751A (es) |
| GB (1) | GB0402492D0 (es) |
| GE (1) | GEP20084361B (es) |
| IL (1) | IL177004A0 (es) |
| MA (1) | MA28348A1 (es) |
| NL (1) | NL1028193C2 (es) |
| NO (1) | NO20063944L (es) |
| PA (1) | PA8623101A1 (es) |
| PE (1) | PE20050772A1 (es) |
| TW (1) | TWI300066B (es) |
| UY (1) | UY28737A1 (es) |
| WO (1) | WO2005077935A1 (es) |
| ZA (1) | ZA200606236B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009503050A (ja) * | 2005-08-04 | 2009-01-29 | ファイザー・リミテッド | ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物 |
| CN101277960A (zh) * | 2005-09-29 | 2008-10-01 | 默克公司 | 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物 |
| CA2625877A1 (en) * | 2005-10-18 | 2007-04-26 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| ES2402581T3 (es) | 2006-02-23 | 2013-05-06 | Pfizer Limited | Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4 |
| JP5243274B2 (ja) * | 2006-02-23 | 2013-07-24 | ファイザー・リミテッド | ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン |
| DK2176220T3 (da) | 2007-08-07 | 2013-06-10 | Takeda Pharmaceutical | Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| HUE052714T2 (hu) * | 2014-05-29 | 2021-05-28 | Mitsubishi Tanabe Pharma Corp | Új pirrolidin vegyület és alkalmazás melanokortin receptor agonistaként |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| CA2995188A1 (en) * | 2015-08-04 | 2017-02-09 | Astellas Pharma Inc. | Piperazine derivative |
| CN112694436B (zh) * | 2020-12-30 | 2022-07-08 | 济南周行医药科技有限公司 | 一种槟榔碱的合成方法 |
| CN114211258B (zh) * | 2021-11-04 | 2023-09-26 | 江阴市大久金属科技有限公司 | 高精密无缝钢管制备工艺 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053710B (en) * | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
| ATE341327T1 (de) * | 2001-02-28 | 2006-10-15 | Merck & Co Inc | Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten |
-
2004
- 2004-02-04 GB GBGB0402492.3A patent/GB0402492D0/en not_active Ceased
-
2005
- 2005-01-26 AU AU2005213538A patent/AU2005213538A1/en not_active Abandoned
- 2005-01-26 CA CA2555800A patent/CA2555800C/en not_active Expired - Fee Related
- 2005-01-26 JP JP2006551945A patent/JP4031814B2/ja not_active Expired - Fee Related
- 2005-01-26 WO PCT/IB2005/000208 patent/WO2005077935A1/en active Application Filing
- 2005-01-26 BR BRPI0507435-5A patent/BRPI0507435A/pt not_active IP Right Cessation
- 2005-01-26 AP AP2006003699A patent/AP2006003699A0/xx unknown
- 2005-01-26 GE GEAP20059564A patent/GEP20084361B/en unknown
- 2005-01-26 CN CNA2005800075736A patent/CN1930146A/zh active Pending
- 2005-01-26 AT AT05702363T patent/ATE511507T1/de not_active IP Right Cessation
- 2005-01-26 EA EA200601279A patent/EA011159B1/ru not_active IP Right Cessation
- 2005-01-26 EP EP05702363A patent/EP1716135B1/en active Active
- 2005-01-26 KR KR1020067015811A patent/KR100830763B1/ko not_active IP Right Cessation
- 2005-02-02 PE PE2005000122A patent/PE20050772A1/es not_active Application Discontinuation
- 2005-02-03 TW TW094103372A patent/TWI300066B/zh active
- 2005-02-03 UY UY28737A patent/UY28737A1/es not_active Application Discontinuation
- 2005-02-03 AR ARP050100409A patent/AR048232A1/es not_active Application Discontinuation
- 2005-02-04 NL NL1028193A patent/NL1028193C2/nl not_active IP Right Cessation
- 2005-02-04 PA PA20058623101A patent/PA8623101A1/es unknown
-
2006
- 2006-07-20 IL IL177004A patent/IL177004A0/en unknown
- 2006-07-27 ZA ZA200606236A patent/ZA200606236B/xx unknown
- 2006-08-03 EC EC2006006751A patent/ECSP066751A/es unknown
- 2006-08-03 CR CR8545A patent/CR8545A/es not_active Application Discontinuation
- 2006-08-04 MA MA29242A patent/MA28348A1/fr unknown
- 2006-09-04 NO NO20063944A patent/NO20063944L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA011159B1 (ru) | 2009-02-27 |
| TWI300066B (en) | 2008-08-21 |
| WO2005077935A1 (en) | 2005-08-25 |
| ATE511507T1 (de) | 2011-06-15 |
| KR20060127125A (ko) | 2006-12-11 |
| GEP20084361B (en) | 2008-04-29 |
| UY28737A1 (es) | 2005-09-30 |
| IL177004A0 (en) | 2006-12-10 |
| EP1716135A1 (en) | 2006-11-02 |
| JP4031814B2 (ja) | 2008-01-09 |
| CN1930146A (zh) | 2007-03-14 |
| CA2555800C (en) | 2010-06-15 |
| PA8623101A1 (es) | 2006-05-16 |
| NL1028193C2 (nl) | 2006-04-20 |
| KR100830763B1 (ko) | 2008-05-19 |
| MA28348A1 (fr) | 2006-12-01 |
| EA200601279A1 (ru) | 2006-12-29 |
| JP2007534668A (ja) | 2007-11-29 |
| TW200526625A (en) | 2005-08-16 |
| ECSP066751A (es) | 2006-11-16 |
| ZA200606236B (en) | 2008-04-30 |
| PE20050772A1 (es) | 2005-10-31 |
| CR8545A (es) | 2007-09-03 |
| NO20063944L (no) | 2006-10-31 |
| BRPI0507435A (pt) | 2007-07-03 |
| AU2005213538A1 (en) | 2005-08-25 |
| NL1028193A1 (nl) | 2005-08-08 |
| GB0402492D0 (en) | 2004-03-10 |
| AP2006003699A0 (en) | 2006-08-31 |
| CA2555800A1 (en) | 2005-08-25 |
| EP1716135B1 (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048232A1 (es) | Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| UY37513A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| RU2008114378A (ru) | Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| RU2013151803A (ru) | Бициклические гетероциклические соединения и их применения в терапии | |
| AR069309A1 (es) | Derivados de imidazo[1,2-a] piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos. | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| AR054484A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| CL2008002132A1 (es) | Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras. | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| CO2017008809A2 (es) | Compuestos de benzoxaborol y uso de los mismos | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR100073A1 (es) | Sulfonas heterocíclicas sustituidas con heteroarilos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |